European Heart Journal Impact Factor

The first signal is obvious. EHJ sits in the global cardiology flagship tier.

The second signal is normalization. The JCI of 8.05 is unusually strong. That matters because cardiology has wide variance in citation patterns across intervention, imaging, prevention, epidemiology, heart failure, and guidelines-linked clinical research. EHJ is not just benefitting from a citation-heavy field. It is outperforming the field by a large margin.

The third signal is cleanliness. The JIF without self-cites is 32.6, which stays very close to the headline JIF. That tells you the number is not being materially inflated by internal citation concentration.

The JCR row above is the authoritative impact factor on this page. For the longer directional view, the table below uses the open Scopus-based impact score series as a trend proxy.

Directionally, the open citation signal is up from 6.58 in 2023 to 7.46 in 2024. The larger pattern is that EHJ remains stable at a very high baseline even as cardiovascular publishing has shifted between guideline-heavy cycles, registry volume, and post-pandemic normalization.

This is the profile of a durable owner journal, not a temporary citation spike.

The common mistake is to see a very high impact factor and assume the journal is mostly screening for prestige.

That is not how EHJ usually works in practice. The journal is more often screening for:

• broad cardiovascular consequence
• strong clinical or translational relevance
• practice, policy, or guideline significance
• a package that speaks to an international cardiology readership

That means an excellent subspecialty paper can still be the wrong fit. The metric confirms the journal is elite. It does not make the paper broad enough for it.

In our pre-submission review work on manuscripts targeting EHJ, the repeat problem is not weak methods. It is a weak field-level consequence case.

The paper may be good cardiology, but it still reads too local, too observational, or too narrow for a flagship audience.

In our pre-submission review work on manuscripts targeting EHJ, four failure patterns recur.

The study is too local. Single-center or geographically narrow observational work often fails when the generalizability case is weak.

The result is good but not field-shaping. A respectable cardiology study is not automatically an EHJ study.

The paper lacks strong practice or guideline consequence. Editors at this level want a reason the result matters beyond one narrow corner of the field.

The first-page message is too soft. The title, abstract, and first figure sequence should already communicate why the journal's broad cardiology readership needs the paper.

If that sounds familiar, a European Heart Journal submission readiness check is usually more useful than another round of cosmetic revision.

The impact factor does not tell you whether the paper is broad enough, whether the ESC-facing consequence is clear enough, or whether JACC, Circulation, JAMA Cardiology, or a narrower cardiovascular title is the better owner.

That is the trap. The metric describes the journal. It does not validate the manuscript.